ArticleCancer2021

Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events.

Edward H Ip et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.